<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04062435</url>
  </required_header>
  <id_info>
    <org_study_id>KCI_02</org_study_id>
    <nct_id>NCT04062435</nct_id>
  </id_info>
  <brief_title>Corneal Uptake of Riboflavin Eye Drops</brief_title>
  <official_title>Corneal Uptake of Riboflavin Eye Drops</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Luzerner Kantonsspital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Luzerner Kantonsspital</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall objective of this study is to optimise the corneal cross-linking standard
      protocol in terms of a more economical use of the resource &quot;medical personnel&quot; and in terms
      of increased patient participation. If it can be shown that the riboflavin necessary for
      corneal cross-linking does not necessarily have to be applied directly on the cornea (as
      currently performed by the nurses), but can also be applied in the inferior fornix (as it
      would be performed by patients in the context of self-application), then it would be
      conceivable to transfer this task from medical staff to the patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This national single-centre, experimental, randomized and controlled trial will comprise two
      parallel arms. The intervention to be studied will be an alternative application of
      riboflavin drops in the inferior fornix. As comparator serves a conventional riboflavin drop
      application directly on the center of the cornea. Our research hypothesis is that the
      application of riboflavin drops in the inferior fornix is not inferior to the corneal
      application with respect to the resulting riboflavin concentrations in the anterior chamber;
      which represents a sufficient corneal impregnation with riboflavin. This study is randomized
      but not blinded. Recruitment is anticipated to start in September 2019 and is scheduled to
      last 1-2 months. We will enroll 12 patients in each trial arm.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">December 1, 2019</start_date>
  <completion_date type="Actual">March 1, 2020</completion_date>
  <primary_completion_date type="Actual">March 1, 2020</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Quantitative changes in anterior chamber riboflavin concentrations over a time period of 60 min for both application sites (inferior fornix and cornea)</measure>
    <time_frame>Three hours</time_frame>
    <description>Correlating to our standard CXL protocol, the application phase lasts 60 min and the riboflavin drops will be applied by the principle investigator every 5 minutes on the cornea in the conventional and in the inferior fornix in the interventional group. The drop application will be performed in an upright position and without an eyelid speculum. During the application phase, fluorophotometric measurements will be repeated every 15 minutes and changes in corneal and anterior chamber riboflavin concentrations will be documented.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">36</enrollment>
  <condition>Keratoconus</condition>
  <arm_group>
    <arm_group_label>Interventional Group</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Peschke®TE 0.25 % application in the INFERIOR FORNIX
Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Group</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Peschke®TE 0.25 % application on the CORNEA
Peschke®TE 0.25 % (Peschke Trade, Hünenberg, Switzerland) eye drops, 1 drop every 5 minutes over 60 minutes by the Principal Investigator.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drop application in the inferior fornix</intervention_name>
    <description>See Arms</description>
    <arm_group_label>Interventional Group</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Drop application on the cornea</intervention_name>
    <description>See Arms</description>
    <arm_group_label>Control Group</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy clinical staff members of the Dept. of Ophthalmology at the Lucerne Cantonal
             Hospital will be evaluated for study inclusion.

          -  Signed written informed consent form

        Exclusion Criteria:

          -  Aged &lt; 18 years

          -  Any ocular or systemic diseases with ocular side effects

          -  Medication with potential ocular side effects

          -  Epilepsia, due to the flickering light of the fluorophotometer used to measure
             anterior chamber riboflavin concentration
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Katja Iselin, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Dept. of Ophthalmology, Lucerne Cantonal Hospital</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Dept. of Ophthalmology, Lucerne Cantonal Hospital</name>
      <address>
        <city>Lucerne</city>
        <zip>6004</zip>
        <country>Switzerland</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Switzerland</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>August 19, 2019</study_first_submitted>
  <study_first_submitted_qc>August 19, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">August 20, 2019</study_first_posted>
  <last_update_submitted>March 28, 2020</last_update_submitted>
  <last_update_submitted_qc>March 28, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Luzerner Kantonsspital</investigator_affiliation>
    <investigator_full_name>Katja Iselin</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>Cross-linking, Riboflavin, Fluorophotometry, FluorotronTM Master</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Keratoconus</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

